Targeting the SR-A1-c-Myc axis to augment cardiac resident reparative macrophage proliferation may be a promising therapeutic strategy for doxorubicin-induced cardiomyopathy.
The SR-A1-c-Myc axis may represent a promising target to treat DiCM through augmentation of cardiac resident reparative macrophage proliferation.
Zhang et al. (Fri,) studied this question.